Search results
Novavax awaits FDA decision on whether its next COVID shot can be offered in US
WSAU Wausau· 10 hours agoBy Michael Erman (Reuters) - Novavax will only be able to offer a COVID-19 vaccine in the United States this autumn if regulators accept the shot it has ...
Novavax (NASDAQ:NVAX) Trading 3.4% Higher
ETF DAILY NEWS· 23 hours agoNovavax, Inc. (NASDAQ:NVAX – Get Free Report) shot up 3.4% during trading on Wednesday . 1,132,956 shares changed hands during trading, a decline of 90% from the average session ...
3 Things You Need to Know If You Buy Novavax Today | The Motley Fool
The Motley Fool· 3 days agoNovavax (NVAX 5.30%) stock has both soared and plummeted at times in recent years. Investors...
COVID’s New ‘FLiRT’ Variants—What To Know As Experts Fear Summer Surge
Forbes· 3 days agoNew coronavirus variants dubbed “FLiRT” are circulating the world and growing dominant in the U.S.,...
Why Novavax (NVAX) Stock Price Appreciated 14% on Monday
Zacks via Yahoo Finance· 4 days agoNovavax (NVAX) surges after one of its top shareholders drops a proxy campaign against the company....
Better Buy: Inovio Pharmaceuticals vs. Novavax
Motley Fool via Yahoo Finance· 3 days agoWhich of these two biotechs can outperform the other moving forward? Let's take a look. NVAX data by YCharts The case for Novavax Novavax earned approval...
Why Vaccine Stocks Rallied This Week | The Motley Fool
The Motley Fool· 19 hours agoShares of vaccine stocks Moderna (MRNA 1.58%), Novavax (NVAX 2.31%), and BioNTech SE (BNTX -2.07%)...
The FLiRT COVID variants: What are they and are they more contagious?
Reuters· 19 hours agoThe moniker FLiRT is an acronym for the locations of the mutations the variants share on the virus'...
Moderna and Novavax Hope for Early Launch of This Year’s Covid-19 Shots, Despite FDA Delay
Barrons.com· 5 days agovaccine makers say that the Food and Drug Administration’s delay in designing this fall’s Covid-19 ...
This Stock Just More Than Doubled in 1 Day: Is It a Buy?
Motley Fool via Yahoo Finance· 6 days agoVaccine maker Novavax (NASDAQ: NVAX) isn't dead in the water after all. Though the past 18 months...